Severe COVID-19 was characterized by 1) an increase of RvE1 and MaR2 levels versus non-affected donors and those in less severe COVID-19 groups; 2) an increase of 14-HDHA versus healthy donors and mild COVID-19 patients; 3) an increase of PGD2 versus less severe COVID-19 groups. This evidence concerns the gene PEG10 and COVID-19.